Newfound Research’s Bio-Techne TECH Stock Holding History

Newfound Research’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-712	Closed	-$62K	–	139
2022 Q2	$62K	Sell	712 -420	-37%	-$39.4K	0.13%	109
2022 Q1	$123K	Buy	+1,132	New	+$117K	0.16%	77
2021 Q3	–	Sell	-404	Closed	-$45K	–	129
2021 Q2	$45K	Buy	+404	New	+$42.5K	0.09%	108
2021 Q1	–	Sell	-516	Closed	-$41K	–	153
2020 Q4	$41K	Buy	+516	New	+$37.4K	0.11%	122

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return

Newfound Research's TECH Position: Q3 2022 in Review

Newfound Research sold out of Bio-Techne (TECH) in Q3 2022, closing a stake of 712 shares — an estimated $62K sold.

Newfound Research first reported a position in TECH in Q4 2020 and held it in 4 quarters. The position peaked at $123K in Q1 2022. 536 funds tracked by Wall St. Rank hold TECH as of Q3 2022.

Newfound Research reported no remaining Bio-Techne position as of Q3 2022 after selling out during the quarter.
Newfound Research sold 712 Bio-Techne shares in Q3 2022, an estimated $62K.
Newfound Research first reported a position in Bio-Techne in Q4 2020 and held it in 4 quarters.
Newfound Research's Bio-Techne position peaked at $123K in Q1 2022.
536 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2022.

Based on Newfound Research's 13F filing for Q3 2022, filed 13 Oct 2022.